Gujarat Themis Biosyn Ltd.

Gujarat Themis Biosyn Ltd. was incorporated in 1981 jointly by GIIC
 and chemosyn (P) Ltd.  GIBL commenced production in Aug.1985 by
 producing antibiotic erythromycin, and erythromycin salts and
 formulations.  GTBL was a sick company which was forced to
 discontinue production because of accumulated losses.  The company
 was takenover during June 1991 by pharmaceutical Business Group India
 Ltd; a unique consortium of five competing drug companies - Themis
 Chemicals, Kopran, Anant & Co., Cadila and Lyka Labs.  The company
 has technical and financial collaboration with Yuhan Corporation,
 South Korea.  With Yuhan's knowhow, GTBL has become India's first
 company to start commercial production of anti-tubercolis drug,
 rifampicin.
 
 2002-Gujarat Themis Biosyn Ltd has informed  that Mr Rajneesh Anand
 has been appointed as the Managing Director of the Company w e f
 February 01, 2002.
 
 2008
 
 -Gujarat Themis Biosyn Ltd has appointed Mr. S S Lee as an Additional
 Director of the Company.
 
 -The Company has appointed Mr. Rajneesh Anand as Managing Director 
 
 2010
 
 - Gujarat Themis Biosyn Ltd has appointed Mr. Subhash C Kaushik as
 Additional Director of the Company.
 
 2011
 
 -The Board of Directors appointed Mr. Rajneesh Anand as Managing
 Director of the Company
 
 2012
 
 -The Company has received a Rehabilitation Scheme approved by the
 Board of Industrial and Financial Reconstruction (BIFR)
 
 2014
 
 -Mr. Vikas Tarekar has been appointed as a Company Secretary of the
 company.
 
 -Mr. Tapas Guha has been appointed as a CEO of the Company.
 
 2023
 
 -The Company has splits its face value from Rs. 5/- to Rs. 1/-.